Dyax names Todd Bazemore as Chief Commercial Officer Dyax Corp. announced the appointment of Todd Bazemore as Executive Vice President and Chief Commercial Officer. Bazemore will be responsible for leading Dyax’s commercial organization which currently markets KALBITOR for the treatment of acute attacks of hereditary angioedema in patients 12 years of age and older. Bazemore most recently served as Vice President, Managed Markets at Sunovion Pharmaceuticals.
Dyax receives positive opinion for Orphan designation in EU for DX-2930 Dyax announced that the European Medicines Agency Committee for Orphan Medicinal Products has adopted a positive opinion recommending DX-2930 for designation as an orphan medicinal product for the treatment of hereditary angioedema. Dyax is developing DX-2930, an investigational fully human monoclonal antibody inhibitor of plasma kallikrein, as a subcutaneous injection for prevention of HAE attacks.